MECP2 and neoplasm: Therefore, as an evidence of a reduction in MeCP2 activity, we detected significantly higher (p < 0.0001, t-test) L1 mRNA abundance in patient #2 tumour versus adjacent brain (Fig. 1e), as well as significant tumour-restricted hypomethylation of the canonical L1-Ta promoter (p < 0.0001, t-test) (Fig. 1f).